Pauline Verdijk

ORCID: 0000-0003-2272-2736
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • T-cell and B-cell Immunology
  • Viral Infections and Immunology Research
  • Respiratory viral infections research
  • vaccines and immunoinformatics approaches
  • Viral gastroenteritis research and epidemiology
  • SARS-CoV-2 and COVID-19 Research
  • Virus-based gene therapy research
  • Cell Adhesion Molecules Research
  • CAR-T cell therapy research
  • Chemokine receptors and signaling
  • Pneumonia and Respiratory Infections
  • Monoclonal and Polyclonal Antibodies Research
  • RNA Interference and Gene Delivery
  • Influenza Virus Research Studies
  • Immune Cell Function and Interaction
  • Bacterial Infections and Vaccines
  • Animal Disease Management and Epidemiology
  • Cytokine Signaling Pathways and Interactions
  • Antimicrobial Resistance in Staphylococcus
  • Cellular transport and secretion
  • Image Processing Techniques and Applications
  • Tracheal and airway disorders
  • Cancer Immunotherapy and Biomarkers
  • Cytomegalovirus and herpesvirus research

Intravacc (Netherlands)
2013-2020

Leiden University Medical Center
2001-2013

Radboud University Nijmegen
2005-2013

Radboud University Medical Center
2006-2013

Consejo Nacional de Investigaciones Científicas y Técnicas
2013

Instituto Tecnológico de Santo Domingo
2013

Instituto de Desarrollo Tecnológico para la Industria Química
2013

We report the efficient identification of four human histocompatibility leukocyte antigen (HLA)-A(*)0201-presented cytotoxic T lymphocyte (CTL) epitopes in tumor-associated PRAME using an improved "reverse immunology" strategy. Next to motif-based HLA-A(*)0201 binding prediction and actual stability assays, analysis vitro proteasome-mediated digestions polypeptides encompassing candidate was incorporated epitope procedure. Proteasome cleavage pattern analysis, particular determination...

10.1084/jem.193.1.73 article EN The Journal of Experimental Medicine 2001-01-01

The success of immunotherapy with dendritic cells (DC) to treat cancer is dependent on effective migration the lymph nodes and subsequent activation antigen-specific T cells. In this study, we investigated fate DC after intradermal (i.d.) or intranodal (i.n.) administration consequences for immune activating potential vaccines in melanoma patients.DC were i.d. i.n. administered 25 patients metastatic scheduled regional node resection. To track vivo scintigraphic imaging by...

10.1158/1078-0432.ccr-08-2729 article EN Clinical Cancer Research 2009-03-25

Dendritic cells (DC) are professional antigen-presenting of the immune system that play a key role in regulating T cell-based immunity. In vivo, capacity DC to activate depends on their ability migrate cell areas lymph nodes as well maturation state. Depending cytokine-secreting profile, able skew response specific direction. particular, IL-12p70 producing drive towards helper 1 type response. A serious disadvantage current clinical grade ex vivo generated monocyte-derived is poor...

10.1007/s00262-008-0489-2 article EN cc-by-nc Cancer Immunology Immunotherapy 2008-03-05

Success of immunotherapy with dendritic cells (DC) to treat cancer is highly dependent on their interaction and activation antigen specific T cells. To maximize DC-T cell contact accurate delivery the therapeutic into lymph node, or efficient trafficking DC nodes patient essential. Since responses are seen in some patients but not others, monitoring injected may be major importance. Tracking magnetic resonance (MR) imaging a non-invasive method that provides detailed anatomical information...

10.1002/ijc.22385 article EN International Journal of Cancer 2006-12-12

Anticancer dendritic cell (DC) vaccines require the DCs to relocate lymph nodes (LN) trigger immune responses. However, these migration rates are typically very poor. Improving targeting of ex vivo generated LNs might increase vaccine efficacy and reduce costs. We investigated DC in humans under different conditions.HLA-A*02:01 patients with melanoma were vaccinated mature loaded tyrosinase gp100 peptides together keyhole limpet hemocyanin (NCT00243594). For this study, received an...

10.1158/1078-0432.ccr-12-1879 article EN Clinical Cancer Research 2013-02-05

Abstract Electroporation of dendritic cells (DC) with mRNA encoding tumor-associated antigens (TAA) for cancer immunotherapy has been proved efficient and clinically safe. It obviates prior knowledge CTL Th epitopes in the antigen leads to presentation multiple several HLA alleles. Here we studied migration capacity expression mRNA-electroporated DC (mRNA-DC) lymph nodes after vaccination melanoma patients. were electroporated gp100 or tyrosinase, labeled indium-111 superparamagnetic iron...

10.1158/0008-5472.can-08-3920 article EN Cancer Research 2009-03-25

Upon activation, tissue residing immature dendritic cells (DC) start to migrate towards the draining lymph node and mature into efficient antigen-presenting cells. During maturation DC loose their capacity endocytose antigens, change surface expression of adhesion molecules, chemokine receptors, costimulatory morphology. We employed 2D-PAGE mass spectrometry identify additional differentially expressed proteins in DC. Human monocyte-derived were matured with LPS protein profiles compared...

10.1002/eji.200324241 article EN European Journal of Immunology 2003-12-19

Human respiratory syncytial virus (RSV) is a major cause of lower tract infections in early infancy and elderly. A pediatric vaccine against RSV would not only prevent morbidity mortality amongst infants young children but could also reduce transmission to The RSVΔG consists live-attenuated that lacks the G attachment protein. severely impaired binding host cells exhibits reduced infectivity preclinical studies. Intranasal immunization cotton rats with protected replication wildtype RSV,...

10.1016/j.vaccine.2020.07.029 article EN cc-by Vaccine 2020-07-25

BACKGROUND: Influenza vaccine production capacity is still insufficient to meet global demand in case of a pandemic. To expand worldwide influenza capacity, solid and transferable egg-based process was established that suitable for upscaling technology transfer manufacturers low- middle-income countries. As proof-of-concept, the safety immunogenicity pandemic whole inactivated virus (WIV) (H5N1) monovalent seasonal WIV (H3N2) were evaluated phase I clinical trial adults. METHODS: Subjects...

10.1080/21645515.2015.1012004 article EN Human Vaccines & Immunotherapeutics 2015-03-09

Compelling evidence supports an intimate link in time and space between eukaryotic pre-mRNA synthesis processing nucleocytoplasmic transport of mature mRNA. In this study, we analyzed the kinetic behavior these processes a quantitative manner. We used FISH confocal scanning laser microscopy to detect transcripts produced by inducible human cytomegalovirus immediate early (HCMV-IE) expression system. Upon induction, large amount accumulated nuclear foci at or near their transcription sites...

10.1242/jcs.115.2.321 article EN Journal of Cell Science 2002-01-15

One of the main challenges in early clinical research with respiratory syncytial virus (RSV) live-attenuated vaccines (LAVs) is to assess immunogenicity healthy adults. Healthy adults will have preexisting levels serum neutralizing antibodies that could prematurely neutralize LAV and underestimate potential effect vaccine on immune system. Data prevalence distribution titers (VNTs) limited there no absolute threshold for protection against RSV-infection can serve as an eligibility criterion...

10.1080/21645515.2019.1688040 article EN cc-by-nc-nd Human Vaccines & Immunotherapeutics 2019-11-01

Introduction of Haemophilus influenzae type b (Hib) vaccine in low- and middle-income countries has been limited by cost availability Hib conjugate vaccines for a long time. It was previously recognized the Institute Translational Vaccinology (Intravacc, originating from former Unit National Public Health [RIVM] Netherlands Vaccine [NVI]) that local production would increase affordability sustainability thereby help to speed up introduction these countries. A new affordable non-infringing...

10.4161/hv.28924 article EN Human Vaccines & Immunotherapeutics 2014-05-02

<div>Abstract<p><b>Purpose:</b> Anticancer dendritic cell (DC) vaccines require the DCs to relocate lymph nodes (LN) trigger immune responses. However, these migration rates are typically very poor. Improving targeting of <i>ex vivo</i> generated LNs might increase vaccine efficacy and reduce costs. We investigated DC <i>in in humans under different conditions.</p><p><b>Experimental Design:</b><i>HLA-A*02:01</i>...

10.1158/1078-0432.c.6522075 preprint EN 2023-03-31

<div>Abstract<p><b>Purpose:</b> Anticancer dendritic cell (DC) vaccines require the DCs to relocate lymph nodes (LN) trigger immune responses. However, these migration rates are typically very poor. Improving targeting of <i>ex vivo</i> generated LNs might increase vaccine efficacy and reduce costs. We investigated DC <i>in in humans under different conditions.</p><p><b>Experimental Design:</b><i>HLA-A*02:01</i>...

10.1158/1078-0432.c.6522075.v1 preprint EN 2023-03-31
Coming Soon ...